All In Biotech

Drug Trial Radar · NCT05509634

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 754 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

754

Actual

Start

Sep 21, 2022

Primary completion

Jun 19, 2023

Study completion Aug 30, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.

Conditions

  • Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Interventions

  • HR20013 for injection;dexamethasoneDrug

    HR20013 for injection;Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

  • fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasoneDrug

    fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response during the overall phase after the start of the first cisplatin administrationTime frame: 0-120 hours after the start of the first cisplatin administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center Yuexiu Campus

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.